# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the pric...
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $38 price...
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-...
4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)))), a leading clinical-stage genetic medicines company focused on ...
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price t...